UK health technology assessment body NICE says the cost-effectiveness estimates for the nasal spray for treating hard-to-treat depression are much higher than what it considers to be cost-effective.
The UK's National Institute for Health and Care Excellence (NICE) has for the second time recommended against making Janssen's antidepressant spray Spravato (esketamine) available on England's National Health Service.
NICE initially issued for consultation in January a draft guidance that said it could not recommend the drug for routine...
Create an account to read this article
Already a subscriber?
Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.
ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.
The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.
The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.
The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.
Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
